Pyoderma Gangrenosum in a Patient with Advanced Rectal Cancer Treated with Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy

2019 ◽  
Vol 85 (11) ◽  
pp. 572-574
Author(s):  
Mary Henningsgaard ◽  
Michelle Sittig ◽  
Carolina Velez-Mejia ◽  
Armando Sardi
Keyword(s):  
Rectal Cancer ◽  
Pyoderma Gangrenosum ◽  
Intraperitoneal Chemotherapy ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Advanced Rectal Cancer

scholarly journals Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis from Rectal Cancer

2013 ◽  
Vol 20 (4) ◽  
pp. 1088-1092 ◽  
Author(s):  
Konstantinos I. Votanopoulos ◽  
Katrina Swett ◽  
Aaron U. Blackham ◽  
Chukwuemeka Ihemelandu ◽  
Perry Shen ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Peritoneal Carcinomatosis ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy

scholarly journals ASSOCIATION BETWEEN PELVIC EXENTERATION AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY FOR RECTAL CANCER

2021 ◽  
Vol 68 (2) ◽  
pp. 154-156
Author(s):  
Nicolae Bacalbasa ◽  
◽  
Irina Balescu ◽  
Adnan Al Aloul ◽  
◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Rectal Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Pelvic Exenteration ◽  
Locally Advanced ◽  
Radical Resection ◽  
Peritoneal Metastases ◽  
Surgical Strategies

Colorectal cancer spreads via multiple pathways, the most commonly encountered ways being represented by the peritoneal and hematogenous ones as well as by direct contiguity. At this time significant benefits in terms of survival have been reported in cases presenting locally advanced lesions and for those presenting extended peritoneal lesions of peritoneal carcinomatosis especially if radical resection is achievable. In this respect, certain authors went further and investigated whether the association of the two surgical strategies – extended pelvic resections and cytoreductive surgery of the peritoneal metastases could improve survival in cases in which both patterns of spread are present. Meanwhile, the possibility of association of hyperthermic intraperitoneal chemotherapy (HIPEC) was also investigated. The aim of the current study is to review and analyze the most relevant studies conducted on this issue.

scholarly journals Total Pelvic Exenteration, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy for Rectal Cancer with Associate Peritoneal Metastases: Surgical Strategies to Optimize Safety

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3478
Author(s):  
Jean-Jacques Tuech ◽  
Jean Pinson ◽  
François-Xavier Nouhaud ◽  
Gregory Wood ◽  
Thomas Clavier ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Treatment Option ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Pelvic Exenteration ◽  
Locally Advanced ◽  
Peritoneal Metastases ◽  
R0 Resection ◽  
Total Pelvic Exenteration

Background: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a curative treatment option for patients with peritoneal carcinomatosis. Total pelvic exenteration (TPE) is an established treatment option for locally advanced pelvic malignancy. These two procedures have high mortality and morbidity, and therefore, their combination is not currently recommended. Herein, we reported our experience on TPE associated with CRS/HIPEC with a critical analysis for rectal cancer with associate peritoneal metastases. Methods: From March 2006 to August 2020, 319 patients underwent a CRS/HIPEC in our hospital. Among them, 16 (12 men and four women) underwent an associated TPE. The primary endpoints were perioperative morbidity and mortality. Results: There was locally recurrent rectal cancer in nine cases, six locally advanced primary rectal cancer, and a recurrent appendiceal adenocarcinoma. The median Peritoneal Cancer Index (PCI) was 8. (4–16). Mean duration of the surgical procedure was 596 min (420–840). Complete cytoreduction (CC0) was achieved in all patients, while clear resection (R0) margins on the resected pelvic organs were achieved in 81.2% of cases. The median hospital stay was 46 days (26–129), and nine patients (56.2%) experienced severe complications (grade III to V) that led to death in two cases (12.5%). The total reoperation rate for patients was 6/16 (37.5%) and 3/16 (18.75%) with percutaneous radiological-guided drainage. Conclusions: In summary, TPE/extended TPE (ETPE) associated with CRS/HIPEC may be a reasonable procedure in selected patients at expert centers. Pelvic involvement should not be considered a definitive contraindication for CRS/HIPEC in patients with resectable peritoneal surface diseases if a R0 resection could be achieved on all sites. However, the morbidity and the mortality are high with this combination of treatment, and further research is needed to assess the oncologic benefit and quality of life before such a radical approach can be recommended.

Sign in / Sign up

Export Citation Format

Share Document